SCHEDULE 13D/A: Manning Boosts Verrica Stake to 49.9% After Unit Purchases

Paul B. Manning and affiliated entities increased their beneficial ownership in Verrica Pharmaceuticals Inc. to 49.9% through recent purchases of common stock and warrants.

Summary

• Paul B. Manning and affiliated entities (PBM Capital Investments, LLC and BKB Growth Investments, LLC) collectively beneficially own 8,056,031 shares of Verrica Pharmaceuticals Inc. common stock.
• This aggregate ownership represents 49.9% of the Issuer's outstanding common stock, based on 15,989,861 shares outstanding as of November 25, 2025.
• On November 25, 2025, Mr. Manning purchased 1,375,380 investment units, each consisting of one share of common stock and a Series C warrant for one-quarter of a share.
• On the same date, BKB Growth Investments, LLC purchased 2,750,762 investment units, each consisting of one share of common stock and a Series C warrant for one-quarter of a share.
• Each investment unit was acquired at a price of $4.2425.
• The reported share numbers reflect a 1-for-10 reverse stock split effected by the Issuer on July 24, 2025.

Sentiment

Score: 7

Explanation: The significant increase in beneficial ownership by a key insider and affiliated entities, coupled with a substantial investment, suggests strong confidence in the company's future. While the filing itself is factual and not promotional, the action of increasing a stake to nearly 50% is a positive signal for investors.

Positives

• Increased insider ownership by Paul B. Manning and affiliated entities, signaling confidence in the company's future.
• Significant investment of $4.2425 per unit by key stakeholders.

Risks

• Mr. Manning is not entitled to exercise warrants if it causes his aggregate beneficial ownership to exceed 49.99% of the outstanding common stock.
• BKB Growth Investments, LLC is not entitled to exercise warrants if it causes its aggregate beneficial ownership to exceed 19.99% of the outstanding common stock.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance regarding the company's future performance or strategic direction, beyond the reporting persons' continued significant ownership.

Industry Context

This filing indicates a significant increase in insider ownership for Verrica Pharmaceuticals, a company operating in the pharmaceutical sector. Such a move by a major investor like Paul B. Manning, known for his involvement in healthcare and life sciences, could be interpreted by the market as a strong vote of confidence in the company's long-term prospects, potentially related to its product pipeline or market position within the dermatology or broader pharmaceutical industry. It suggests a belief in the company's intrinsic value despite any recent corporate actions like the reverse stock split.

Comparison to Industry Standards

• This filing primarily details changes in beneficial ownership by a major investor group, rather than operational or financial results that can be directly compared to industry benchmarks or specific competitor projects.
• The increase in insider ownership to nearly 50% is a substantial stake, which is higher than typical institutional or individual investor holdings in many publicly traded pharmaceutical companies, often indicating a more active, strategic interest rather than a purely passive investment.
• For example, in many biotech firms, even large institutional investors rarely hold such a dominant position without seeking board representation or strategic influence.

Stakeholder Impact

• Shareholders: Increased insider ownership may be viewed positively, signaling confidence and potentially aligning management/major investor interests with shareholder value.
• Employees: No direct impact mentioned, but a strong major investor could provide stability or strategic direction.
• Customers/Suppliers/Creditors: No direct impact mentioned.

Key Dates

Recommendation

The significant increase in beneficial ownership by Paul B. Manning and his affiliated entities to nearly 50% is a strong vote of confidence, suggesting a belief in the company's long-term value. This insider buying, especially after a reverse stock split, could be a positive indicator. However, without additional information on the company's operational performance, strategic initiatives, or market conditions, a 'hold' recommendation is prudent. Investors should monitor future developments and the impact of this increased insider stake on corporate strategy and performance before making further investment decisions. The large stake also raises questions about potential future control or strategic shifts.

Keywords

Verrica Pharmaceuticals, Paul B. Manning, PBM Capital, BKB Growth Investments, Schedule 13D, Insider Ownership, Stock Purchase, Warrants, Reverse Stock Split, Pharmaceuticals